Andrea Sartore-Bianchi Selected Research

Panitumumab (Vectibix)

11/2022	Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial.
1/2020	Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study.
11/2019	Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.
9/2019	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
1/2018	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case.
12/2016	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.
6/2016	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
10/2015	The genomic landscape of response to EGFR blockade in colorectal cancer.
7/2015	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
11/2014	Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrea Sartore-Bianchi Research Topics

Disease

89	Colorectal Neoplasms (Colorectal Cancer) 11/2022 - 05/2005
67	Neoplasms (Cancer) 10/2022 - 04/2005
11	Neoplasm Metastasis (Metastasis) 01/2022 - 06/2012
11	Disease Progression 01/2022 - 06/2012
5	Circulating Neoplastic Cells 05/2021 - 02/2014
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2017
4	Microsatellite Instability 01/2021 - 01/2019
4	Renal Cell Carcinoma (Grawitz Tumor) 01/2017 - 05/2004
3	Carcinoma (Carcinomatosis) 11/2021 - 04/2005
3	Malignant Mesothelioma 10/2007 - 11/2002
2	Exanthema (Rash) 11/2022 - 06/2016
2	Anemia 11/2022 - 04/2005
2	Stomach Neoplasms (Stomach Cancer) 01/2021 - 11/2019
2	Fatigue 01/2020 - 06/2016
2	Rectal Neoplasms (Rectal Cancer) 01/2020 - 09/2019
2	Colonic Neoplasms (Colon Cancer) 01/2019 - 10/2013
1	Turcot syndrome 01/2022
1	Bites and Stings (Sting) 05/2021
1	Respiratory Insufficiency (Respiratory Failure) 02/2021
1	Thymoma (Thymic Carcinoma) 02/2021
1	Myasthenia Gravis 02/2021
1	Drug-Related Side Effects and Adverse Reactions 01/2021
1	Adenocarcinoma 01/2021
1	Breast Neoplasms (Breast Cancer) 09/2020
1	Inflammation (Inflammations) 01/2020

Drug/Important Bio-Agent (IBA)

24	ErbB Receptors (EGF Receptor)IBA 01/2022 - 05/2005
24	Cetuximab (Erbitux)FDA Link 11/2021 - 05/2005
23	Panitumumab (Vectibix)FDA Link 11/2022 - 05/2005
17	Monoclonal AntibodiesIBA 11/2019 - 05/2005
15	Biomarkers (Surrogate Marker)IBA 01/2021 - 10/2009
11	Oxaliplatin (Eloxatin)FDA LinkGeneric 02/2022 - 05/2004
8	Circulating Tumor DNAIBA 05/2021 - 02/2014
8	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2014
7	AntibodiesIBA 01/2022 - 08/2010
6	Trastuzumab (Herceptin)FDA Link 01/2021 - 11/2015
6	Pharmaceutical PreparationsIBA 01/2021 - 01/2017
6	Lapatinib (GW572016)FDA Link 01/2021 - 11/2015
6	regorafenibIBA 01/2019 - 05/2013
5	entrectinibIBA 10/2022 - 12/2015
5	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2019
5	DNA (Deoxyribonucleic Acid)IBA 05/2021 - 01/2018
5	Fluorouracil (Carac)FDA LinkGeneric 01/2020 - 12/2016
5	Phosphotransferases (Kinase)IBA 01/2017 - 06/2013
5	Calcibiotic Root Canal SealerIBA 12/2016 - 02/2014
4	Temozolomide (Temodar)FDA LinkGeneric 01/2022 - 01/2017
3	Cell-Free Nucleic AcidsIBA 01/2021 - 07/2017
3	pertuzumabIBA 01/2021 - 01/2020
3	Leucovorin (Folinic Acid)FDA Link 01/2020 - 09/2019
2	pembrolizumabIBA 10/2022 - 01/2022
2	VaccinesIBA 01/2022 - 01/2022
2	Anaplastic Lymphoma KinaseIBA 01/2022 - 12/2015
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 04/2005
2	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 01/2020
2	trastuzumab deruxtecanIBA 01/2021 - 01/2020
2	Tyrosine Kinase InhibitorsIBA 01/2021 - 01/2020
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 12/2016
2	Capecitabine (Xeloda)FDA Link 01/2020 - 10/2013
2	Biological ProductsIBA 07/2017 - 05/2014
2	Dacarbazine (DIC)FDA LinkGeneric 01/2017 - 04/2013
2	Codon (Codons)IBA 06/2016 - 10/2010
2	Growth Factor ReceptorsIBA 03/2014 - 05/2005
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2014 - 06/2012
2	MMEIBA 10/2007 - 11/2002
2	Interleukin-2 (IL2)IBA 10/2004 - 11/2002
1	larotrectinibIBA 10/2022
1	dostarlimabIBA 10/2022
1	disitamab vedotinIBA 03/2022
1	trastuzumab duocarmazineIBA 03/2022
1	mRNA VaccinesIBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	Bevacizumab (Avastin)FDA Link 01/2022
1	avelumabIBA 11/2021
1	InterferonsIBA 05/2021
1	Cisplatin (Platino)FDA LinkGeneric 02/2021
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2021
1	SteroidsIBA 02/2021
1	Pyridostigmine Bromide (Pyridostigmine)FDA LinkGeneric 02/2021
1	Intravenous Immunoglobulins (IVIG)FDA Link 02/2021
1	encorafenibIBA 01/2021
1	Granzymes (Granzyme)IBA 01/2021
1	Everolimus FDA Link 01/2021
1	Topoisomerase I InhibitorsIBA 01/2021
1	ChromatinIBA 01/2021
1	Apoptosis Regulatory ProteinsIBA 01/2021
1	Forkhead Transcription Factors (Forkhead Box Proteins)IBA 01/2021
1	abemaciclibIBA 09/2020
1	palbociclibIBA 09/2020
1	ribociclibIBA 09/2020
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 09/2020

Therapy/Procedure

58	Therapeutics 10/2022 - 06/2005
14	Drug Therapy (Chemotherapy) 11/2022 - 05/2005
5	Immunotherapy 01/2022 - 05/2004
4	Retreatment 02/2022 - 02/2019
4	Precision Medicine 01/2021 - 11/2011
1	Contraindications 02/2021
1	Critical Care (Surgical Intensive Care) 02/2021
1	Plasma Exchange 02/2021
1	Artificial Respiration (Mechanical Ventilation) 02/2021
1	Radiotherapy 02/2021